1.50
price up icon1.35%   0.02
pre-market  プレマーケット:  1.51   0.01   +0.67%
loading
前日終値:
$1.48
開ける:
$1.5
24時間の取引高:
647.55K
Relative Volume:
0.28
時価総額:
$89.40M
収益:
$5.03M
当期純損益:
$-185.41M
株価収益率:
-0.4854
EPS:
-3.09
ネットキャッシュフロー:
$-139.79M
1週間 パフォーマンス:
+2.74%
1か月 パフォーマンス:
-3.23%
6か月 パフォーマンス:
-89.75%
1年 パフォーマンス:
-88.10%
1日の値動き範囲:
Value
$1.45
$1.525
1週間の範囲:
Value
$1.40
$1.59
52週間の値動き範囲:
Value
$1.1001
$16.52

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
名前
Pliant Therapeutics Inc
Name
セクター
Healthcare (1153)
Name
電話
650-481-6770
Name
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
職員
171
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
PLRX's Discussions on Twitter

PLRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PLRX
Pliant Therapeutics Inc
1.50 89.40M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-04 再開されました Cantor Fitzgerald Neutral
2025-03-04 ダウングレード Needham Buy → Hold
2025-03-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-03-03 ダウングレード Stifel Buy → Hold
2025-02-10 ダウングレード Canaccord Genuity Buy → Hold
2025-02-10 ダウングレード Citigroup Buy → Neutral
2025-02-10 ダウングレード H.C. Wainwright Buy → Neutral
2025-02-10 ダウングレード JP Morgan Overweight → Neutral
2025-02-10 ダウングレード Oppenheimer Outperform → Perform
2025-02-10 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-02-10 ダウングレード Wells Fargo Overweight → Equal Weight
2024-09-09 再開されました Leerink Partners Outperform
2023-12-08 開始されました Wells Fargo Overweight
2023-05-18 開始されました Canaccord Genuity Buy
2023-04-13 開始されました Robert W. Baird Outperform
2022-12-14 開始されました Stifel Buy
2022-12-07 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Buy
2022-07-20 開始されました SVB Leerink Outperform
2022-05-25 開始されました Cantor Fitzgerald Overweight
2021-12-10 開始されました Oppenheimer Outperform
2021-11-24 開始されました RBC Capital Mkts Outperform
2021-11-03 開始されました H.C. Wainwright Buy
2021-04-20 開始されました BTIG Research Buy
2021-04-05 開始されました Citigroup Buy
2020-06-29 開始されました Citigroup Buy
2020-06-29 開始されました Cowen Outperform
2020-06-29 開始されました Needham Buy
2020-06-29 開始されました Piper Sandler Overweight
すべてを表示

Pliant Therapeutics Inc (PLRX) 最新ニュース

pulisher
Apr 21, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant ... - Bluefield Daily Telegraph

Apr 21, 2025
pulisher
Apr 21, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - TradingView

Apr 21, 2025
pulisher
Apr 10, 2025

PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Apr 10, 2025
pulisher
Apr 09, 2025

Pliant Therapeutics stock hits 52-week low at $1.2 amid sharp decline - Investing.com

Apr 09, 2025
pulisher
Apr 07, 2025

PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 07, 2025
pulisher
Apr 07, 2025

Major Breakthrough: Pliant Reveals Latest Bexotegrast Research Data in Three Key Presentations - Stock Titan

Apr 07, 2025
pulisher
Apr 07, 2025

Pliant Therapeutics Announces Upcoming Presentations at the - GlobeNewswire

Apr 07, 2025
pulisher
Apr 05, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - ACCESS Newswire

Apr 05, 2025
pulisher
Apr 03, 2025

Pliant Therapeutics: An Activist On Deck - Seeking Alpha

Apr 03, 2025
pulisher
Apr 02, 2025

symbol__ Stock Quote Price and Forecast - CNN

Apr 02, 2025
pulisher
Apr 01, 2025

PLRX stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com Canada

Apr 01, 2025
pulisher
Mar 28, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus

Mar 28, 2025
pulisher
Mar 27, 2025

PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics – PLRX - menafn

Mar 26, 2025
pulisher
Mar 23, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph

Mar 23, 2025
pulisher
Mar 23, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire Inc.

Mar 23, 2025
pulisher
Mar 21, 2025

TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Pliant Therapeutics Inc - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Pliant discontinues Phase 2b/3 trial of IPF treatment bexotegrast - Pulmonary Fibrosis News

Mar 21, 2025
pulisher
Mar 21, 2025

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com

Mar 21, 2025
pulisher
Mar 19, 2025

Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright - Defense World

Mar 19, 2025
pulisher
Mar 17, 2025

Pliant Therapeutics Announces Interim Phase 1 Data for - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Markets Insider

Mar 17, 2025
pulisher
Mar 17, 2025

Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial - Marketscreener.com

Mar 17, 2025
pulisher
Mar 14, 2025

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - Yahoo Finance

Mar 14, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics adopts shareholder rights plan By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals

Mar 13, 2025
pulisher
Mar 13, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve

Mar 13, 2025
pulisher
Mar 13, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics adopts shareholder rights plan - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan

Mar 13, 2025
pulisher
Mar 09, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM

Mar 09, 2025

Pliant Therapeutics Inc (PLRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
大文字化:     |  ボリューム (24 時間):